Arete Wealth Advisors LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

Arete Wealth Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 34.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,772 shares of the biopharmaceutical company’s stock after buying an additional 22,013 shares during the quarter. Arete Wealth Advisors LLC’s holdings in Pfizer were worth $2,299,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on PFE shares. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Stock Down 1.6 %

Shares of NYSE:PFE opened at $24.30 on Friday. Pfizer Inc. has a 1-year low of $24.24 and a 1-year high of $31.54. The company’s fifty day moving average is $25.93 and its two-hundred day moving average is $26.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $137.79 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the company posted $0.10 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.